Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)

Amylyx Pharmaceuticals has reported Preferred Stock Liabilities over the past 1 years, most recently at $239.4 million for Q4 2021.

  • Quarterly results put Preferred Stock Liabilities at $239.4 million for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $239.4 million (changed N/A YoY), and the annual figure for FY2021 was $239.4 million, changed.
  • Preferred Stock Liabilities for Q4 2021 was $239.4 million at Amylyx Pharmaceuticals, up from $134.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for AMLX hit a ceiling of $239.4 million in Q4 2021 and a floor of $7.7 million in Q1 2021.